주요 신경계질환의 항우울제 처방 패턴: 2017년 제도 변경 이전
Prescription Pattern of Antidepressants in Korea for Major Neurological Disorders: Before the Policy Change in 2017
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: It is well known that patients with neurological disorders are vulnerable to depression. However, in Korea, National Health Insurance services had banned non-psychiatrists from prescribing antidepressants for more than 2 months until January 2017. Now, neurologists are able to prescribe antidepressants to patients with only four neurological disorders. Due to this recent change in national health insurance policy, there will be a large change in the prescription pattern of antidepressants. In this study, we performed an analysis of antidepressant prescription patterns in Korea prior to this recent policy change. Methods: The source population of this retrospective cohort study is the Health Insurance Review & Assessment Service database. We analyzed the claim database for patients who have one of four major neurologic disorders and had healthcare documentation submitted by healthcare providers between January 1, 2011 and December 31, 2016. Results: During 2012-2016, antidepressant prescription rates of 6.21% (127,192 of a total 2,048,165 patients), 9.93% (81,861 out of 824,290), 10.12% (173,582 of 1,714,776), and 13.36% (48,530 of 363,347) were found for cerebrovascular disease, epilepsy, dementia, and Parkinson’s disease respectively. The most frequently prescribed antidepressant in cerebrovascular disease and epilepsy was tricyclic antidepressants (TCAs). In Parkinson’s disease and dementia, the most frequently used antidepressant was selective serotonin reuptake inhibitors. Conclusions: The overall prescription rate of antidepressants was much lower than the estimated rates reported in other countries. TCAs were the primarily prescribed antidepressant. It is now expected that TCAs will be replaced by newer antidepressants.
Abstract
Background: It is well known that patients with neurological disorders are vulnerable to depression. However, in Korea, National Health Insurance services had banned non-psychiatrists from prescribing antidepressants for more than 2 months until January 2017. Now, neurologists are able to prescribe antidepressants to patients with only four neurological disorders. Due to this recent change in national health insurance policy, there will be a large change in the prescription pattern of antidepressants. In this study, we performed an analysis of antidepressant prescription patterns in Korea prior to this recent policy change. Methods: The source population of this retrospective cohort study is the Health Insurance Review & Assessment Service database. We analyzed the claim database for patients who have one of four major neurologic disorders and had healthcare documentation submitted by healthcare providers between January 1, 2011 and December 31, 2016. Results: During 2012-2016, antidepressant prescription rates of 6.21% (127,192 of a total 2,048,165 patients), 9.93% (81,861 out of 824,290), 10.12% (173,582 of 1,714,776), and 13.36% (48,530 of 363,347) were found for cerebrovascular disease, epilepsy, dementia, and Parkinson’s disease respectively. The most frequently prescribed antidepressant in cerebrovascular disease and epilepsy was tricyclic antidepressants (TCAs). In Parkinson’s disease and dementia, the most frequently used antidepressant was selective serotonin reuptake inhibitors. Conclusions: The overall prescription rate of antidepressants was much lower than the estimated rates reported in other countries. TCAs were the primarily prescribed antidepressant. It is now expected that TCAs will be replaced by newer antidepressants.
참고문헌 (24)
- World Health Statistics 2016: monitoring health for the SDGs sustainable development goals, "World Health Organization", World Health Organization, 10~ (2016)
- Health at a glance 2017, "OECD Indicators", OECD, 191~ (2017)
- Hellmann-Regen J, "Depressive syndromes in neurological disorders", Eur Arch Psychiatry Clin Neurosci, 263(Suppl 2), pp.S123~S136 (2013)
- Kanner AM, "Should neurologists be trained to recognize and treat comorbid depression of neurologic disorders? Yes", Epilepsy Behav, 6, pp.303~311 (2005)
- Kanner AM, "Depression in epilepsy : prevalence, clinical semiology, pathogenic mechanisms, and treatment", Biol Psychiatry, 54, pp.388~398 (2003)
- Ehrt U, "Depressive symptom profile in Parkinson's disease : a comparison with depression in elderly patients without Parkinson's disease", Int J Geriatr Psychiatry, 21, pp.252~258 (2006)
- Robinson RG, "Poststroke depression : prevalence, diagnosis, treatment, and disease progression", Biol Psychiatry, 54, pp.376~387 (2003)
- Kitching D, "Depression in dementia", Aust Prescr, 38, pp.209~2011 (2015)
- Allain H, "Depression in Parkinson's disease", BMJ, 320, pp.1287~1288 (2000)
- Mayberg HS, "Depression in Parkinson's disease : a biochemical and organic viewpoint", Adv Neurol, 65, pp.49~60 (1995)
- Koenig AM, "First-line pharmacotherapies for depression-what is the best choice", Pol Arch Med Wewn, 119, pp.478~486 (2009)
- Geddes JR, "SSRIs versus other antidepressants for depressive disorder", Cochrane Database Syst Rev, (2), pp.CD001851~ (2000)
- Kessler RC, "The epidemiology of major depressive disorder : results from the national comorbidity survey replication(NCS-R)", JAMA, 289, pp.3095~3105 (2003)
- Alonso J, "Prevalence of mental disorders in Europe: results from the European study of the epidemiology of mental disorders (ESEMeD)project", Acta Psychiatr Scand Suppl, (420), pp.21~27 (2004)
- Ishikawa H, "Lifetime and 12-month prevalence, severity and unmet need for treatment of common mental disorders in Japan : results from the final dataset of world mental health Japan survey", Epidemiol Psychiatr Sci, 25, pp.217~229 (2016)
- Chong SA, "The prevalence and impact of major depressive disorder among Chinese, Malays and Indians in an Asian multi-racial population", J Affect Disord, 138, pp.128~136 (2012)
- Cho MJ, "Lifetime and 12-month prevalence of DSM-IV psychiatric disorders among Korean adults", J Nerv Ment Dis, 195, pp.203~210 (2007)
- Anderson IM, "Selective serotonin reuptake inhibitors versus tricyclic antidepressants : a meta-analysis of efficacy and tolerability", J Affect Disord, 58, pp.19~36 (2000)
- Spijker J, "An algorithm for the pharmacological treatment of depression", Acta Psychiatr Scand, 121, pp.180~189 (2010)
- MacGillivray S, "Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care : systematic review and meta-analysis", BMJ, 326, pp.1014~ (2003)
- Barbui C, "Selective serotonin reuptake inhibitors and risk of suicide : a systematic review of observational studies", CMAJ, 180, pp.291~297 (2009)
- Grunebaum MF, "Antidepressants and suicide risk in the United States, 1985-1999", J Clin Psychiatry, 65, pp.1456~1462 (2004)
- Nakagawa A, "Association of suicide and antidepressant prescription rates in Japan, 1999-2003", J Clin Psychiatry, 68, pp.908~916 (2007)
- "Korean Statistical Information Service. 2017년 사망원인 통계" (2018)[URL]